Article Text
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
QUESTION: Does hormone therapy (HT) improve health related quality of life (HRQL) in postmenopausal women with coronary artery disease (CAD)?
Design
Randomised {allocation concealed}*, blinded {patients, clinicians, and outcome assessors}* placebo controlled trial with follow up to 3 years.
Setting
Outpatient and community settings in 20 clinical centres in the US.
Patients
2763 postmenopausal women <80 years of age (mean age 67 y) with documented CAD (previous myocardial infarction [MI], >50% luminal narrowing of a major vessel on angiography, or a previous coronary revascularisation procedure). Exclusion criteria were MI or revascularisation procedure in the previous 6 months, previous hysterectomy, contraindications to HT, HT in the previous 3 …
Footnotes
Source of funding: Wyeth-Ayerst Research.
For correspondence: Dr M A Hlatky, Stanford University, School of Medicine, Stanford, CA, USA. hlatky{at}stanford.edu
A modified version of this abstract appears in Evidence-Based Medicine and Evidence-Based Mental Health